Jurcic Joseph G
Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Curr Oncol Rep. 2003 Sep;5(5):391-8. doi: 10.1007/s11912-003-0025-7.
Acute promyelocytic leukemia (APL) is characterized by a translocation between the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17. Reverse-transcription polymerase chain reaction (RT-PCR) amplification of PML-RARalpha messenger RNA can establish the diagnosis of APL, predict response to all-trans retinoic acid and arsenic trioxide, detect minimal residual disease, and predict relapse. Quantitative "real-time" RT-PCR techniques may improve residual disease assessment by facilitating more rapid and standardized results. APL provides a useful model in which therapy is targeted to an underlying genetic aberration and treatment is adapted based on monitoring of residual disease.
急性早幼粒细胞白血病（APL）的特征是15号染色体上的早幼粒细胞白血病基因（PML）与17号染色体上的维甲酸受体α（RARα）基因之间发生易位。对PML-RARα信使核糖核酸进行逆转录聚合酶链反应（RT-PCR）扩增可确立APL的诊断，预测对全反式维甲酸和三氧化二砷的反应，检测微小残留病，并预测复发情况。定量“实时”RT-PCR技术可通过促进获得更快速和标准化的结果来改善残留病评估。APL提供了一个有用的模型，其中治疗针对潜在的基因畸变，并根据残留病监测情况调整治疗方案。
